Table 3.

Estimation of adaptation rates of carbon ion radiotherapy in the United States.

Disease site	Estimated patients eligible for CIRT in 2019, No.	GHMC adaption rate [12, 13]	GHMC estimation	NIRS adaption rate [13, 33]	NIRS estimation	Korean adaptation rate [13]	Korean estimation	US estimation for 2019
Glioblastoma	5205	—	—	—	—	—	—	1041a
Head and neck	4154	0.38	1578	0.10	415	0.10	415	415
Hepatocellular carcinoma	31 120	0.25	7780	0.12	3734	0.12	3734	3734
Cholangiocarcinoma	4036	0.25	1109	0.12	484	0.12	484	484
Pancreas	28 695	—	—	0.02	574	0.02	574	574
Non–small cell lung cancer	129 816	0.10	12 982	0.14	18 174	0.14	18 174	18 174
Prostate	143 836	0.15	21 575	0.43	61 849	0.43	61 849	61 849
Soft tissue sarcomas	12 381	0.80	9905	—	—	0.30	3714	3714

Abbreviations: CIRT, carbon-ion radiotherapy; GHMC, Gunma University Heavy Ion Medical Center; NIRS, National Institute of Radiological Sciences.

^aBased on an estimate of 0.20 adaptation rate.